SynBiotic SE completes successfully capital increase and places all new shares

EQS-News: SynBiotic SE

/ Key word(s): Capital Increase

SynBiotic SE completes successfully capital increase and places all new shares
31.10.2022 / 11:05 CET/CEST

The issuer is solely responsible for the content of this announcement.

SynBiotic SE completes successfully capital increase and places all new shares

 

Munich, October 31, 2022

 

SynBiotic SE, as Europe’s largest listed group of companies in the hemp and cannabis sector, has successfully completed the cash capital increase resolved on October 28, 2022. All 191,739 new shares were placed at the subscription price of EUR 13.00 per new share. The proceeds from the capital increase will be used to finance the business activities and expansion of SynBiotic SE through acquisitions.

 

SynBiotic SE CEO Lars Müller commented, “The successful closing and full placement of this capital increase demonstrates the great interest in cannabis in Germany and in SynBiotic SE. Together with the capital increase a few weeks ago, we have raised a total of over EUR 4 million in new capital. With the publication of the key point paper last week on the legalization of recreational cannabis in Germany, it became clear that we are optimally positioned and will be the big winner of legalization. We will use the new funds in a targeted manner to further expand our leading position.”

 

The execution of this capital increase is expected to be entered into the Company’s commercial register in early to mid November 2022. Inclusion in trading on the primary market of the Düsseldorf Stock Exchange and delivery of the new Shares are expected to take place in mid to late November 2022.

 

About SynBiotic SE:

 

SynBiotic SE is the largest listed group of companies in Europe in the hemp and cannabis sector and pursues an EU-focused buy & build investment strategy. The group of companies covers the entire supply chain from cultivation to production to retail from field to shelf. One of the company’s core businesses is the research & development, production and marketing of cannabinoid and terpene-based solutions to major societal problems such as pain, sleep and anxiety. In doing so, SynBiotic SE is active not only in the dietary supplement and cosmetics markets, but also in the medical and, in the future, recreational cannabis sector.

 

Further information is available at https://www.synbiotic.com.

 

Investor contact

Lars Mueller

presse@synbiotic.com
 


31.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this